Akorn, Inc. Names Mark M. Silverberg as Vice President, Global Quality and Regulatory Compliance.

BUFFALO GROVE, Ill. -- Akorn, Inc. (AMEX:AKN) today announced the appointment of Mark M. Silverberg as Vice President, Global Quality and Regulatory Compliance. Mr. Silverberg brings over twenty-nine years of quality and regulatory affairs experience with pharmaceuticals, parenterals, and medical devices to his new role at Akorn. Having served with Abbott Laboratories in numerous management positions, he brings a portfolio of experience in regulatory compliance programming, quality systems development and deployment, and quality assurance / quality control operations.

Arthur S. Przybyl, president and chief executive officer, stated, "We are very excited to have Mark join our senior management team. He brings substantial quality and regulatory affairs experience in specialty pharmaceuticals and parenterals to Akorn. We are confident that his quality assurance and regulatory expertise will be a great asset to us."

About Akorn, Inc.

Akorn, Inc. manufactures and markets sterile specialty pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois and Somerset, New Jersey and markets and distributes an extensive line of hospital and ophthalmic pharmaceuticals. Additional information is available at the Company's website at www.akorn.com.

Any statements made by Akorn, Inc. ("we", "us", "our", "Akorn" or the "Company") in this press release that are forward looking are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that important factors may affect the Company's actual results and could cause such results to differ materially from forward-looking statements made by or on behalf of the Company. Such factors include, but are not limited to, risks and uncertainties relating to (i) the ability to generate cash from operations sufficient to meet the Company's working capital requirements, (ii) the necessity of complying with various regulatory procedures in the manufacture of drug products, (iii) the Company's ability to acquire, develop, finance, test, produce and market new products, including the availability of materials to produce products, (iv) the resolution of the FDA compliance issues at the Company's Decatur, Illinois manufacturing facility and the outcome of other legal proceedings involving the Company, (v) patent protection for the Company's intellectual property or trade secrets, and (vi) other risks detailed from time to time in filings the Company makes with the Securities and Exchange Commission including, but not limited to, those risks referenced under the caption "Factors That May Affect Future Results" in Item 1 of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2004.